Pharmaceutical stocks are getting more attention these days as the global drug market is expected to reach $1.21 trillion in 2025, showing why the industry matters so much. The growth is driven by new treatments coming out and more people needing specialty medicines.
Within this environment, AbbVie (ABBV) delivered third-quarter 2025 results that beat what Wall Street was expecting. The company brought in $15.78 billion in revenue, up 9.1% from the same quarter last year and beating analyst estimates of $15.58 billion.
